A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Assess the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Dec 2018
At a glance
- Drugs PXL 770 (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Proof of concept; Therapeutic Use
- Sponsors Poxel
- 30 Aug 2018 According to a Poxel media release, the company expects to initiate this study in 2019.
- 18 Jul 2018 According to an Poxel media release, in second half of 2018, company will under go the preparation of this study, which includes, an IND application to the US FDA, manufacturing of drug product and validation of clinical sites.
- 25 Jan 2018 According to an Poxel media release, this trial is expected to initiate during the second half of 2018.